Research ExplorerPublicationsNeurofilament light chain in serum for the diagnosis of amyo...

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

Standard

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. / Verde, Federico; Steinacker, Petra; Weishaupt, Jochen H; Kassubek, Jan; Oeckl, Patrick; Halbgebauer, Steffen; Tumani, Hayrettin; von Arnim, Christine A F; Dorst, Johannes; Feneberg, Emily; Mayer, Benjamin; Müller, Hans-Peter; Gorges, Martin; Rosenbohm, Angela; Volk, Alexander E; Silani, Vincenzo; Ludolph, Albert C; Otto, Markus.

In: J NEUROL NEUROSUR PS, Vol. 90, No. 2, 02.2019, p. 157-164.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Verde, F, Steinacker, P, Weishaupt, JH, Kassubek, J, Oeckl, P, Halbgebauer, S, Tumani, H, von Arnim, CAF, Dorst, J, Feneberg, E, Mayer, B, Müller, H-P, Gorges, M, Rosenbohm, A, Volk, AE, Silani, V, Ludolph, AC & Otto, M 2019, 'Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis', J NEUROL NEUROSUR PS, vol. 90, no. 2, pp. 157-164. https://doi.org/10.1136/jnnp-2018-318704

APA

Verde, F., Steinacker, P., Weishaupt, J. H., Kassubek, J., Oeckl, P., Halbgebauer, S., Tumani, H., von Arnim, C. A. F., Dorst, J., Feneberg, E., Mayer, B., Müller, H-P., Gorges, M., Rosenbohm, A., Volk, A. E., Silani, V., Ludolph, A. C., & Otto, M. (2019). Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J NEUROL NEUROSUR PS, 90(2), 157-164. https://doi.org/10.1136/jnnp-2018-318704

Vancouver

Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J NEUROL NEUROSUR PS. 2019 Feb;90(2):157-164. https://doi.org/10.1136/jnnp-2018-318704

Bibtex

@article{91dd17bb5aee421f934be78d2f99f5b2,
title = "Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis",
abstract = "OBJECTIVE: To determine the diagnostic and prognostic performance of serum neurofilament light chain (NFL) in amyotrophic lateral sclerosis (ALS).METHODS: This single-centre, prospective, longitudinal study included the following patients: 124 patients with ALS; 50 patients without neurodegenerative diseases; 44 patients with conditions included in the differential diagnosis of ALS (disease controls); 65 patients with other neurodegenerative diseases (20 with frontotemporal dementia, 20 with Alzheimer's disease, 19 with Parkinson's disease, 6 with Creutzfeldt-Jakob disease (CJD)). Serum NFL levels were measured using the ultrasensitive single molecule array (Simoa) technology.RESULTS: Serum NFL levels were higher in ALS in comparison to all other categories except for CJD. A cut-off level of 62 pg/mL discriminated between ALS and all other conditions with 85.5% sensitivity (95% CI 78% to 91.2%) and 81.8% specificity (95% CI 74.9% to 87.4%). Among patients with ALS, serum NFL correlated positively with disease progression rate (rs=0.336, 95% CI 0.14 to 0.506, p=0.0008), and higher levels were associated with shorter survival (p=0.0054). Serum NFL did not differ among patients in different ALS pathological stages as evaluated by diffusion-tensor imaging, and in single patients NFL levels were stable over time.CONCLUSIONS: Serum NFL is increased in ALS in comparison to other conditions and can serve as diagnostic and prognostic biomarker. We established a cut-off level for the diagnosis of ALS.",
keywords = "Journal Article",
author = "Federico Verde and Petra Steinacker and Weishaupt, {Jochen H} and Jan Kassubek and Patrick Oeckl and Steffen Halbgebauer and Hayrettin Tumani and {von Arnim}, {Christine A F} and Johannes Dorst and Emily Feneberg and Benjamin Mayer and Hans-Peter M{\"u}ller and Martin Gorges and Angela Rosenbohm and Volk, {Alexander E} and Vincenzo Silani and Ludolph, {Albert C} and Markus Otto",
note = "{\textcopyright} Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2019",
month = feb,
doi = "10.1136/jnnp-2018-318704",
language = "English",
volume = "90",
pages = "157--164",
journal = "J NEUROL NEUROSUR PS",
issn = "0022-3050",
publisher = "BMJ PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

AU - Verde, Federico

AU - Steinacker, Petra

AU - Weishaupt, Jochen H

AU - Kassubek, Jan

AU - Oeckl, Patrick

AU - Halbgebauer, Steffen

AU - Tumani, Hayrettin

AU - von Arnim, Christine A F

AU - Dorst, Johannes

AU - Feneberg, Emily

AU - Mayer, Benjamin

AU - Müller, Hans-Peter

AU - Gorges, Martin

AU - Rosenbohm, Angela

AU - Volk, Alexander E

AU - Silani, Vincenzo

AU - Ludolph, Albert C

AU - Otto, Markus

N1 - © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2019/2

Y1 - 2019/2

N2 - OBJECTIVE: To determine the diagnostic and prognostic performance of serum neurofilament light chain (NFL) in amyotrophic lateral sclerosis (ALS).METHODS: This single-centre, prospective, longitudinal study included the following patients: 124 patients with ALS; 50 patients without neurodegenerative diseases; 44 patients with conditions included in the differential diagnosis of ALS (disease controls); 65 patients with other neurodegenerative diseases (20 with frontotemporal dementia, 20 with Alzheimer's disease, 19 with Parkinson's disease, 6 with Creutzfeldt-Jakob disease (CJD)). Serum NFL levels were measured using the ultrasensitive single molecule array (Simoa) technology.RESULTS: Serum NFL levels were higher in ALS in comparison to all other categories except for CJD. A cut-off level of 62 pg/mL discriminated between ALS and all other conditions with 85.5% sensitivity (95% CI 78% to 91.2%) and 81.8% specificity (95% CI 74.9% to 87.4%). Among patients with ALS, serum NFL correlated positively with disease progression rate (rs=0.336, 95% CI 0.14 to 0.506, p=0.0008), and higher levels were associated with shorter survival (p=0.0054). Serum NFL did not differ among patients in different ALS pathological stages as evaluated by diffusion-tensor imaging, and in single patients NFL levels were stable over time.CONCLUSIONS: Serum NFL is increased in ALS in comparison to other conditions and can serve as diagnostic and prognostic biomarker. We established a cut-off level for the diagnosis of ALS.

AB - OBJECTIVE: To determine the diagnostic and prognostic performance of serum neurofilament light chain (NFL) in amyotrophic lateral sclerosis (ALS).METHODS: This single-centre, prospective, longitudinal study included the following patients: 124 patients with ALS; 50 patients without neurodegenerative diseases; 44 patients with conditions included in the differential diagnosis of ALS (disease controls); 65 patients with other neurodegenerative diseases (20 with frontotemporal dementia, 20 with Alzheimer's disease, 19 with Parkinson's disease, 6 with Creutzfeldt-Jakob disease (CJD)). Serum NFL levels were measured using the ultrasensitive single molecule array (Simoa) technology.RESULTS: Serum NFL levels were higher in ALS in comparison to all other categories except for CJD. A cut-off level of 62 pg/mL discriminated between ALS and all other conditions with 85.5% sensitivity (95% CI 78% to 91.2%) and 81.8% specificity (95% CI 74.9% to 87.4%). Among patients with ALS, serum NFL correlated positively with disease progression rate (rs=0.336, 95% CI 0.14 to 0.506, p=0.0008), and higher levels were associated with shorter survival (p=0.0054). Serum NFL did not differ among patients in different ALS pathological stages as evaluated by diffusion-tensor imaging, and in single patients NFL levels were stable over time.CONCLUSIONS: Serum NFL is increased in ALS in comparison to other conditions and can serve as diagnostic and prognostic biomarker. We established a cut-off level for the diagnosis of ALS.

KW - Journal Article

U2 - 10.1136/jnnp-2018-318704

DO - 10.1136/jnnp-2018-318704

M3 - SCORING: Journal article

C2 - 30309882

VL - 90

SP - 157

EP - 164

JO - J NEUROL NEUROSUR PS

JF - J NEUROL NEUROSUR PS

SN - 0022-3050

IS - 2

ER -